Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma's Phase 2 ZUPREME-1 petrelintide data at EASD 2026 plus Lancet publication signal regulatory momentum.
What changed
Zealand Pharma's Phase 2 ZUPREME-1 petrelintide data at EASD 2026 plus Lancet publication signal regulatory momentum.
Why it matters
Zealand Pharma's Phase 2 ZUPREME-1 petrelintide data at EASD 2026 plus Lancet publication signal regulatory momentum. — impact context not separately stored; see What changed.
← Dashboard
Sep 30, 2026 05:13 AM ET